D. E. Shaw & Co., Inc. Immunovant, Inc. Transaction History

D. E. Shaw & Co., Inc.

$98.6 Billion
Q2 2024

A detailed history of D. E. Shaw & Co., Inc. transactions in Immunovant, Inc. stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 41,479 shares of IMVT stock, worth $1.14 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

41,479

Previous 55,914 25.82%

Holding current value

$1.14 Million

Previous $1.81 Million 39.37%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$25.1 - $31.61 $362,318 - $456,290	-14,435 Reduced 25.82%	41,479 $1.1 Million
Q1 2024 May 15, 2024	SELL	$30.27 - $43.79 $1,574 - $2,277	-52 Reduced 0.09%	55,914 $1.81 Million
Q4 2023 Feb 14, 2024	SELL	$31.31 - $44.19 $2.71 Million - $3.83 Million	-86,598 Reduced 60.74%	55,966 $2.36 Million
Q3 2023 Nov 14, 2023	SELL	$18.55 - $39.96 $11.5 Million - $24.8 Million	-620,647 Reduced 81.32%	142,564 $5.47 Million
Q2 2023 Aug 14, 2023	BUY	$14.2 - $23.75 $4.53 Million - $7.57 Million	318,758 Added 71.72%	763,211 $14.5 Million
Q1 2023 May 15, 2023	BUY	$15.27 - $19.72 $2.23 Million - $2.88 Million	145,983 Added 48.91%	444,453 $6.89 Million
Q4 2022 Feb 14, 2023	BUY	$6.59 - $17.75 $1.97 Million - $5.3 Million	298,470 New	298,470 $5.3 Million
Q1 2022 May 16, 2022	SELL	$5.06 - $8.77 $103,077 - $178,653	-20,371 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$7.33 - $9.32 $149,319 - $189,857	20,371 New	20,371 $174,000
Q2 2021 Aug 16, 2021	SELL	$9.4 - $16.85 $236,118 - $423,255	-25,119 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$13.08 - $49.6 $328,556 - $1.25 Million	25,119 New	25,119 $403,000

Others Institutions Holding IMVT

# of Institutions

220

Shares Held

65.1M

Call Options Held

697K

Put Options Held

629K

View Full List

About Immunovant, Inc.

Ticker IMVT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 129,077,000
Market Cap $3.55B
Description
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of mya...

More about IMVT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

News

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.

Account